Omnicare Given New $64.00 Price Target at Cowen and Company (OCR)
Cowen and Company lifted their price objective on shares of Omnicare (NYSE:OCR) from $61.00 to $64.00 in a research note issued on Monday, Analyst Ratings Network.com reports. The firm currently has an “outperform” rating on the stock. Cowen and Company’s price objective points to a potential upside of 15.32% from the company’s current price.
Shares of Omnicare (NYSE:OCR) traded up 0.45% during mid-day trading on Monday, hitting $55.50. 695,803 shares of the company’s stock traded hands. Omnicare has a one year low of $32.53 and a one year high of $56.39. The stock has a 50-day moving average of $55.08 and a 200-day moving average of $48.06. The company has a market cap of $5.742 billion and a price-to-earnings ratio of 26.70.
Omnicare (NYSE:OCR) last announced its earnings results on Wednesday, July 24th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.87 by $0.03. The company had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. During the same quarter in the previous year, the company posted $0.83 earnings per share. The company’s revenue for the quarter was up 2.2% on a year-over-year basis. On average, analysts predict that Omnicare will post $3.61 earnings per share for the current fiscal year.
Separately, analysts at RBC Capital raised their price target on shares of Omnicare (NYSE:OCR) from $46.00 to $58.00 in a research note to investors on Thursday, July 25th. They now have an “outperform” rating on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Omnicare presently has a consensus rating of “Buy” and a consensus target price of $55.50.
Omnicare, Inc (NYSE:OCR) is a healthcare services company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.